Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a novel anti-TSLP bispecific antibody (GR2002) in healthy Chinese adults: A randomized, placebo-controlled phase 1 trial
Single-dose subcutaneous administration of GR2002 demonstrated favorable safety and tolerability, linear PK, and low immunogenicity. These findings warrant the subsequent clinical development of GR2002.
Authors
- Yian Liu
- Fang Men
- Wei Wang (ORCID: https://orcid.org/0000-0002-1135-8265)
- Shuang Li (ORCID: https://orcid.org/0000-0001-9853-5035)
- Liming Chen (ORCID: https://orcid.org/0000-0003-0200-7989)
- Fan Huang (ORCID: https://orcid.org/0000-0002-9767-089X)
- Jiaojiao Zhang (ORCID: https://orcid.org/0000-0003-1563-6354)
- Chi-Ho Lee
- Qun Gu
- Ziyan Ding (ORCID: https://orcid.org/0000-0002-4242-2450)
- Qingshan Zheng
- Yanting Li
- Yi Fang
- Haifeng Song
- Qian Wang
- Rui Ding
- Suping Niu
- Wenyan Zhao
Institutions
- Xuzhou Medical College (CN)
- Peking University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Peking University People's Hospital (CN)
- Beijing Proteome Research Center (CN)
- Chongqing Medical and Pharmaceutical College (CN)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1016/j.ejps.2026.107432
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00